Aethlon Medical Inc. (AEMD) develops proprietary drug-coated balloon technologies for treating complex peripheral artery disease with a robust pipeline but currently faces zero revenue and substantial net losses.
Investors might consider AEMD as a high-risk, high-reward biotech play with significant potential upside if its proprietary drug-coated balloon technology gains regulatory approval and achieves commercial success. The company's strategic focus on treating complex peripheral artery disease without stenting addresses a major unmet medical need that could generate substantial market share upon product launch. With paid-in capital exceeding $173M, the firm has sufficient resources to navigate the long R&D cycle typical in medtech before reaching profitability.
The stock is highly speculative due to zero revenue and deepening losses, with a net profit of $-13.4M in 2025 suggesting the company is burning through its cash reserves rapidly. Investors face the risk of dilution if management must issue additional shares like the previous $3.5M common share issuance to fund operations before achieving positive cash flow from business activities. The absence of current product sales and a massive retained earnings deficit of $-168M indicates that the company has not yet proven its ability to generate sustainable commercial value.
Aethlon Medical Inc. is a medical device company focused on developing and commercializing advanced cardiovascular technologies, primarily targeting the interventional cardiology market. The firm leverages its proprietary drug-coated balloon technology to treat complex peripheral artery disease without stenting, serving hospitals and interventional cardiologists globally. While recent financial statements show zero revenue in the latest period, the company maintains a strong cash position funded by significant paid-in capital to support its R&D and commercialization efforts.
Financial performance in 2025 was characterized by a net loss of $-13.4M, driven by operating expenses of $9.3M which include $3.2M in general and administrative costs and $2.2M in research and development. The company reported zero revenue for the latest annual period, indicating that its current focus is on advancing its clinical pipeline rather than generating sales from commercial products. Cash flow from operations was negative at $-7.6M, offset partially by cash inflows from financing activities of $7.7M, resulting in a net increase in cash and equivalents to $5.6M.
The medical device industry, particularly interventional cardiology, is highly competitive with established players dominating stent markets while seeking innovation in drug-coated balloon technologies. Regulatory pathways like FDA approval are rigorous and time-consuming, creating barriers to entry but also protecting successful innovators from generic competition once approved. Market demand is driven by an aging population and increasing prevalence of cardiovascular diseases, yet pricing pressure and reimbursement challenges remain constant headwinds for emerging therapies.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $574.2K | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $574.2K | $0 | $0 |
| Operating Expenses | $12.5M | $12.6M | $9.3M |
| Operating Income | $-11.9M | $-12.6M | $-9.3M |
| R&D | $2.7M | $2.5M | $2.2M |
| G&A | $4.5M | $3.9M | $3.2M |
| Stock-Based Comp | $1.1M | $1.2M | $415.2K |
| D&A | $240.9K | $359.1K | $339.6K |
| Depreciation | $240.3K | $358.5K | $339.0K |
| Amortization | $550 | $550 | $550 |
| Other OpEx | $5.2M | $6.2M | $3.9M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | — | — | $10.1K |
| Interest Income | $11.0K | $428.4K | — |
| Pre-Tax Income | $-11.9M | $-12.6M | $-9.3M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-11.9M | $-12.6M | $-9.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-12.0M | $-12.2M | $-13.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-12.0M | $-12.2M | $-13.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $15.1M | $6.2M | $5.9M |
| Cash & Equivalents | $14.5M | $5.4M | $5.5M |
| Accounts Receivable | $0 | — | — |
| Prepaid Expenses | $557.6K | $506.0K | $448.5K |
| Other Current Assets | $0 | $277.8K | $0 |
| Long-Term Assets | $2.4M | $2.0M | $1.4M |
| PP&E (Net) | $1.1M | $1.0M | $676.2K |
| Operating Leases | $1.2M | $883.1K | $601.8K |
| Other LT Assets | $122.5K | $121.9K | $131.7K |
| Total Assets | $17.5M | $8.2M | $7.4M |
| Current Liabilities | $1.5M | $1.8M | $1.9M |
| Accounts Payable | $432.9K | $777.9K | $534.5K |
| Current Leases | $269.4K | $290.6K | $313.0K |
| Deferred Revenue | $0 | — | — |
| Other Current Liab | $802.8K | $761.5K | $1.1M |
| Long-Term Liabilities | $939.6K | $649.8K | $336.7K |
| LT Operating Leases | $939.6K | $649.8K | $336.7K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.4M | $2.5M | $2.2M |
| Shareholders' Equity | $15.1M | $5.8M | $5.1M |
| Paid-In Capital | $157.4M | $160.3M | $173.1M |
| Retained Earnings | $-142.4M | $-154.6M | $-168.0M |
| AOCI | $-6.1K | $-6.9K | $-17.1K |
| Total L&E | $17.5M | $8.2M | $7.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-12.0M | $-12.2M | $-13.4M |
| Non-Cash Adjustments | $2.5M | $1.6M | $5.9M |
| Working Capital Changes | $-986.9K | $499.1K | $-134.2K |
| Cash from Operations | $-10.5M | $-10.1M | $-7.6M |
| Capital Expenditures | $943.1K | $250.9K | $0 |
| Cash from Investing | $-943.1K | $-250.9K | $0 |
| Cash from Financing | $8.9M | $1.3M | $7.7M |
| FX Effect | $-6.0K | $2.1K | $-12.3K |
| Net Change in Cash | $-2.5M | $-9.1M | $69.6K |
| Beginning Cash | $17.2M | $14.6M | $5.5M |
| Ending Cash | $14.6M | $5.5M | $5.6M |
The company operates primarily through its cardiovascular device business, focusing on the development and commercialization of its first-in-class Drug-Coated Balloon (DCB) platforms for peripheral interventions. Revenue streams are currently limited to potential licensing agreements or early-stage sales, reflected by $0 reported revenue in recent periods, while operating expenses consist largely of general and administrative costs totaling $3.2M alongside significant R&D expenditures of $2.2M.
The primary risk is the company's lack of revenue and persistent net losses, evidenced by a $-13.4M profit in 2025, which raises concerns about long-term sustainability and runway. Dependence on successful clinical trials and regulatory approvals from the FDA for its novel technologies creates significant uncertainty regarding future product launch timelines. The market faces high competition from established cardiovascular device manufacturers who may accelerate their own drug-coated balloon programs or offer lower-priced alternatives. Limited operating history and a substantial retained earnings deficit of $-168.0M suggest that investors are betting entirely on the execution of the commercialization strategy rather than current profitability.
Aethlon possesses a first-in-class drug-coated balloon platform designed to deliver anti-proliferative drugs effectively without leaving metal stents in the patient's body, addressing unmet medical needs in complex lesions. The company benefits from proprietary intellectual property and clinical data that differentiates its technology from traditional metallic stents or standard DCBs currently on the market. A strong balance sheet with $5.6M in cash and equivalents provides the liquidity necessary to fund future commercialization and potential strategic partnerships without immediate dilution pressure.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.